• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Slides for the January 12, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
 
FDA Core Presentations, (sNDA) 21–348, ZAVESCA (miglustat) Capsules, Actelion Pharmaceuticals Ltd, for the January 12, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee:
 
Donna Griebel, M.D. Director, Division of Gastroenterology Products ODE III, OND, CDER, FDA (PDF – 112KB)
 
Aisha Peterson Johnson, M.D., M.P.H., M.B.A. Medical Officer Division of Gastroenterology Products ODE III, OND,CDER, FDA (PDF – 584KB)
 
Wiley Chambers, M.D. Acting Director Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products OND, CDER, FDA (PDF – 2.58MB)
 
Ronald Farkas, M.D., Ph.D. Clinical Team Leader Division of Neurology Products ODE I, OND, CDER, FDA (PDF – 57KB)
 
 
 
Sponsor
 
Actelion Pharmaceuticals, Ltd. Core Presentation, (sNDA) 21–348, ZAVESCA (miglustat) Capsules, for the January 12, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 1.92MB)